Get ready to dive into the cutting-edge world of hit-to-lead drug discovery. Look no further than our latest FREE ebook, which explores label-free HTL technologies. Featuring the latest research from leading academics and pharmaceutical companies, including GlaxoSmithKline, Rosalind Franklin Institute and Francis Crick Institute.
This ebook deep dives into adoption and optimisation of label-free hit-to-lead (HTL) technologies, including advanced surface plasmon resonance (SPR) applications for hit identification and validation.
Featured within this ebook are in-depth application notes as well as the latest research from leading academics and pharmaceutical companies, including:
- Anders Bach, Associate Professor at the Department of Drug Design and Pharmacology at the University of Copenhagen
- Researchers from the Francis Crick Institute and GlaxoSmithKline, Dr Andrew Powell, Dr Jacob Bush, Dr Katrin Rittinger, Dr David House and Dr Simon Boulton
- Dr Samuel Liver Manager of the High-Throughput Molecular Discovery Laboratory at the Rosalind Franklin Institute
This ebook examines some of the key topics surrounding label-free HTL technologies, including the below and many more:
- Antibody library screening: high-throughput strategies
Emma Cummins and Ismael Samudio, Centre for Drug Research and Development, Canada and Gregorio Aversa, Abimmune Technologies, Inc - Determining the benefits of kinetic assays over end-point assays
Stuart Knowling and Bob Dass, Sartorius - Label-free technologies for monitoring drug interactions
Kristy McKeating and Jean-François Masson, Université de Montréal and Centre for Self-Assembled Chemical Structures (CSACS)
Download this FREE ebook today to get the full in-depth insight into label-free HTL technologies. This ebook is supported by Sartorius.
